CURRICULUM VITAE Name Alexandre Valério de Mendonça
Institutional address Laboratory of Neurosciences, Faculty of Medicine, 1649-028 Lisbon
Telephone (351)217985183 Telefax (351)217999454 Email[email protected]Present position, institution, starting date Previous positions, institutions, datesOther scientific areas of interest Recent organization of scientific meetings
1. 3rd Ipsen European Symposium on Alzheimer Disease Prevention, Lisbon, 2007.
2. Alzheimer’s Disease without Dementia? Forum Bial Neurologia, Lisbon, 2007(chairman) 3. Coming Soon on AD, satellite symposium, 17th Alzheimer Europe Conference, Estoril,
4. Biomarcadores na Doença de Alzheimer – Da Investigação à Prática Clínica. Lisbon,
5. Encontro Português de Neurodegenerescência e Neuroprotecção. Tomar, 2008 (de
Responsible Researcher for the projects: Neuroprotection by Adenosine (FCT 32424/99) and Depression of Synaptic Transmission Upon Hypoxia (FCT 32422/99). Responsible Researcher for the Faculty of Medicine of Lisbon of the projects: Neuromodulatory Interactions between Adenosine and Arachidonic Acid in Ageing and Hypoxia (PRAXIS PSAU/P/SAU/44/96 1997-1999) and Effect of Free Radicals on Neuronal Function - Neuroprotection by Adenosine (Reitoria UL 1999-2000). Researcher of the projects Modification by Chronic Caffeine Consumption of Adenosine Neuromodulation in the Hippocampus - Possible Relevance for Learning and Memory (FCT 2005-) and Evaluation of the Impact of Chronic Neurological Disorders - A Contribution to the Definition of Relevant Patient-based Outcomes and to the Methodology of Health Services Assessment (FCT 2005-). Coordinator of the project Cognitive Impairment in the Aged - A prospective clinical, neuropsychological, NMR and biochemical study (Fundação Gulbenkian, 2005-). Researcher for the project Biomarkers in Alzheimer’s Disease: the Lipid Homeostasis / Oxidative Stress Connection (Collaboration with Instituto Nacional de Saúde Ricardo Jorge and Instituto Gulbenkian de Ciência; Astra-Zeneca, 2007-2009). Coordinator of the study Neuropsychological Predictors of the Outcome in Non-demented Subjects with Cognitive Complaints (FCT 2009-). Coordinator of the study Pesquisa de Novas Mutações em Genes
Responsáveis por Demência Familiar (collaboration with GenoMed; Grunenthal, 2009) and
the study Estudo Genético de Famílias com Demência sem Mutações Reconhecidas (collaboration with GenoMed; Grunenthal, 2010). NEUROCLINOMICS - Understanding
NEUROdegenerative diseases throught CLINical and OMICS data integration (Sara Madeira, principal investigator, collaboration with Katholieke Universiteit Leuven and Instituto de Engenharia de Sistemas e Computadores, Investigação e Desenvolvimento em Lisboa; FCT, 2011-) Clinical trials Principal Investigator for the clinical trials Propentophylline Long-Term Study (PLUS), GAL-Int 17 e GAL-Int 22. Member of the steering committee of the clinical trial TRIMCI (Triflusal in Mild Cognitive Impairment). Principal Investigator for the clinical trials with rosiglitazone on AD (Reflect-2 and extension studies, 2007-2009). National coordinator and Principal Investigator of the studies 3133K1-3000-W and 3133K1-3001-WW and the corresponding extension studies with the monoclonal antibody bapineuzumab (2008-2010). Clinical trial in AD with the histamine H3 receptor antagonist, SAR110894D (A de Mendonça is National Coordinator).
Member of the Scientific Committee of Associação de Familiares e Amigos de Doentes de Alzheimer. Member of the Scientific Committee of Sociedade Portuguesa de Neurologia. Member of the Scientific Committee of the Faculty of Medicine of Lisbon. Member of Comissão de Ética para a Investigação Clínica (CEIC). Associate member of Memoclínica – Memory Clinic, Lisbon. Portuguese delegate to the Dementia Panel of the European Federation of Neurological Societies (EFNS). Coordinator of the Lisbon centre of the European Alzheimer Disease Consortium (EADC). Senior Editor of Journal of Alzheimer’s Disease. Local Editor of Alzheimer’s Disease and Associated Disorders. Editor of Sinapse
(2008-2010). Referee for Fundação para a Ciência e Tecnologia. Referee for the European Comission FP-7-Health-2007. President of Grupo de Estudos de Envelhecimento Cerebral e Demências (2010-)
Full publications in international journals subjected to peer review
1. de Mendonça A, Ribeiro, JA: Diazepam enhances the inhibitory action of adenosine on
transmission at the frog neuromuscular junction. Eur J Pharmacol 1989 164:347-354.
2. de Mendonça A, Pimentel J, Morgado F, Ferro JM: Mesencephalic hematoma - case
report with necropsy study. J Neurol 1990 237:55-58.
3. de Mendonça A, Ribeiro JA: 2-Chloroadenosine decreases long-term potentiation in the
hippocampal CA1 area of the rat. Neurosci Lett 1990 118:107-111.
4. Melo TP, de Mendonça A, Ferro JM, Crespo M, Carvalho M: An emergency room-based
study of stroke coma. Cerebrovasc Dis 1992 2:93-101.
5. Rosa C, Alves M, Queirós MV, Morgado F, de Mendonça A: Neurological involvement
in rheumatoid arthritis patients with atlanto-axial subluxation - a clinical and neurophysiological study. J Rheumatol 1993 20:248-252.
6. de Mendonça A, Teixeira da Costa JC: The diagnostic test may be negative in
erythromelalgia. Eur J Dermatol 1993 3:153-154.
7. de Mendonça A, Ribeiro JA: Adenosine inhibits the NMDA receptor-mediated excitatory
postsynaptic potential in the hippocampus. Brain Res 1993 606:351-356.
8. Hormigo A, Sales Luís ML, Alves M, de Mendonça A: Electrophysiologic evaluation of
the paraneoplastic syndrome in early stages. Muscle & Nerve 1993 16:1419-1420.
9. de Mendonça A, Ribeiro JA: Endogenous adenosine modulates long-term potentiation in
the hippocampus. Neuroscience 1994 62:385-390.
10. Canhão P, de Mendonça A, Ribeiro JA: 1,3-dipropyl-8-cyclopentylxanthine attenuates the
NMDA response to hypoxia in the rat hippocampus. Brain Res 1994 661:265-273.
11. de Mendonça A, Sebastião AM, Ribeiro JA: Inhibition of NMDA receptor-mediated
currents in isolated rat hippocampal neurons by adenosine A1 receptor activation. NeuroReport 1995 8:1097-1100.
12. Lucchi R, Latini S, de Mendonça A, Sebastião AM, Ribeiro JA: Adenosine by activating
A1 receptors prevents GABAA-mediated actions during hypoxia in the rat hippocampus. Brain Res 1996 732:261-266.
13. de Mendonça A, Ribeiro, JA: Adenosine and neuronal plasticity. Life Sci 1996 60:245-
14. Ribeiro JA, de Mendonça A, Correia de Sá P, Cunha R., Sebastião AM: Purinoceptors
and synaptic plasticity. Drug Dev Res 1996 39 353-360
15. de Mendonça A, Almeida T, Bashir ZI, Ribeiro JA: Endogenous adenosine attenuates
long-term depression and depotentiation in the CA1 region of the rat hippocampus. Neuropharmacology 1997 36:161-167.
16. Carvalho M, de Mendonça A, Miranda PC, Garcia C, Sales Luís ML: Magnetic
stimulation in Alzheimer’s disease. J Neurol 1997 244:304-307.
17. Rocha L, de Mendonça A, Garcia C, Lechner MC: Apolipoprotein E genotype of a
portuguese control population and Alzheimer’s disease patients. Eur J Neurol 1997 5:448-452.
18. de Mendonça A, Ribeiro JA: Activation of metabotropic glutamate receptors attenuate the
inhibitory effects of adenosine in the hippocampus. Br J Pharmacol 1997 121:1541-1548.
19. de Mendonça A, Ribeiro JA: Contribution of metabotropic glutamate receptors to the
depression of excitatory postsynaptic potentials during hypoxia. NeuroReport 1997 8:3667-3671.
20. Simões do Couto F, de Mendonça A, Rocha L, Garcia C, Lechner MC: Age of onset in
Alzheimer’s disease patients with different Apo E genotypes. J Neurol Neurosurg Psychiatry 1998 64:817.
21. Costenla AR, de Mendonça A, Ribeiro JA: Adenosine modulates synaptic plasticity in
hippocampal slices from aged rats. Brain Res 1999 851:228-234.
22. Rocha L, Garcia C, de Mendonça A, Gil JP, Bishop DT, Lechner MC: N-acetyltransferase
(NAT2) genotype and susceptibility to sporadic Alzheimer’s Disease. Pharmacogenetics 1999 9:9-15.
23. Costenla AR, de Mendonça A, Sebastião AM, Ribeiro JA: An adenosine analogue
inhibits NMDA receptor-mediated responses in bipolar cells of the rat retina. Exp Eye Res 1999 68:367-370.
24. Coelho J, de Mendonça A, Ribeiro JA: Presynaptic inhibitory receptors mediate the
depression of synaptic transmission upon hypoxia. Brain Res 2000 869:158-165.
25. de Mendonça A, Sebastião AM, Ribeiro JA: Adenosine: does it have a neuroprotective
role after all? Brain Res Rev 2000 33:258-274.
26. de Mendonça A, Ribeiro JA: Long-term potentiation observed upon blockade of
adenosine A1 receptors in the rat hippocampus is N-methyl-D-aspartate receptor-dependent. Neurosci Lett 2000 291:81-84.
27. Sebastião AM, Cunha RA, de Mendonça A, Ribeiro JA: Modification of adenosine
modulation of synaptic transmission in the hippocampus of aged rats. Br J Pharmacol 2000 131:1629-1634.
28. de Mendonça A, Ribeiro JA: Adenosine and synaptic plasticity. Drug Dev Res 2001
29. Sebastião AM, de Mendonça A, Ribeiro JA: Neuroprotection during hypoxic insults: role
of adenosine. Drug Dev Res 2001 52:291-295.
30. Ribeiro JA, Cunha Reis D, Lopes LV, Coelho JE, Costenla AR, Correia de Sá P, Cunha
R, de Mendonça A, Sebastião AM: Adenosine receptor interactions in the hippocampus. Drug Dev Res 2001 52:337-345.
31. Costenla AR, Lopes LV, de Mendonça A, Ribeiro JA: A functional role for adenosine A3
receptors: modulation of synaptic plasticity in the rat hippocampus. Neurosci Lett 2001 302:53-57.
32. Sebastião AM, de Mendonça A, Moreira T, Ribeiro JA: Activation of synaptic NMDA
receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci 2001 21:8564-8571.
33. de Mendonça A, Costenla AR, Ribeiro JA: Persistence of the neuromodulatory effects of
adenosine on synaptic transmission after long-term potentiation and long-term depression. Brain Res 2002 932:56-60.
34. Cunha R, Coelho JE, Costenla AR, Lopes LV, Parada A, de Mendonça A, Sebastião AM,
Ribeiro JA: Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices. Pharmacol Toxicol 2002 90:208-213.
35. Maia L, de Mendonça A: Does caffeine intake protect from Alzheimer´s disease? Eur J
36. Ribeiro JA, Sebastião AM, de Mendonça A: Adenosine receptors in the nervous system:
pathophysiological implications. Progr Neurobiol 2003 68 377-392.
37. Almeida CG, de Mendonça, Cunha RA, Ribeiro JA: Adenosine promotes recovery from
reactive oxygen species induced lesion in rat hippocampal slices. Neurosci Lett 2003 339:127-130.
38. Ribeiro JA, Sebastião AM, de Mendonça A: Participation of adenosine receptors in
neuroprotection. Drugs News Perspectives 2003 16:80-86.
39. Rebola N, Sebastião AM, de Mendonça A, Ribeiro JA, Oliveira CR, Cunha RA:
Enhanced adenosine A2A receptor facilitation of synaptic transmission in the hippocampus of aged rats. J Neurophysiol 2003 90:1295-1303.
40. Rebola N, Coelho JE, Costenla AR, Lopes LV, Parada A, Oliveira CR, Soares da Silva P,
de Mendonça A, Cunha RA: Decrease of adenosine A1 receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. Eur J Neurosci 2003 18:820-828.
41. Almeida T, Rodrigues RJ, de Mendonça A, Ribeiro JA, Cunha RA: Purinergic P2
receptors trigger adenosine release leading to adenosine A2A receptor activation and facilitation of long-term potentiation in rat hippocampal slices. Neuroscience 2003 122:111-121.
42. de Mendonça A, Guerreiro M, Ribeiro F, Mendes T, Garcia C: Mild cognitive
impairment: focus on the diagnosis. J Mol Neurosci 2004 23:13-17.
43. de Mendonça A, Ribeiro F, Guerreiro M, Garcia C: Frontotemporal mild cognitive
impairment. J Alzheim Dis 2004 6:1-9.
44. de Mendonça A, Ribeiro F, Guerreiro M, Palma T, Garcia C: Clinical significance of
subcortical vascular disease in patients with mild cognitive impairment. Eur J Neurol 2005 12:125-130.
45. Silva BM, de Mendonça A, Ribeiro JA. Long-term depression is not modulated by ATP
receptors in the rat CA1 hippocampal region. Neurosci Lett 2005 383:345-349.
46. Ribeiro F, de Mendonça A, Guerreiro M: Mild cognitive impairment: deficits in cognitive
domains other than memory. Dementia Cogn Geriatr Dis 2006 21:284-290.
47. Coelho JE, Rebola N, Fragata I, Ribeiro JA, de Mendonça A, Cunha RA. Hypoxia-
induced desensitization and internalization of adenosine A1 receptors in the rat hippocampus. Neuroscience 2006 138:1195-1203.
48. Pereira AF, Simões do Couto F, de Mendonça A. The use of laboratory tests in patients
with Mild Cognitive Impairment. J Alzheim Dis 2006 10:53-58.
49. Cerqueira V, de Mendonça A, Minez A, Ramos Dias A, de Carvalho M. The effect of
caffeine on motor excitability. Neurophysiologie Clinique / Clinical Neurophysiology 2006 36:219-226.
50. Rodrigues RJ, Almeida T, de Mendonça A, Cunha RA. Interaction between P2X and
nicotinic acetylcholine receptors in glutamate nerve terminals of the rat hippocampus. J Mol Neurosci. 2006 30:173-176.
51. Ribeiro F, Guerreiro M, de Mendonça A. Verbal learning and memory deficits in mild
cognitive impairment. J Clin Exp Neuropsychol 2007 29:187-197.
52. Ritchie K, Carrière I, Portet F, de Mendonça A, Dartigues JF, Rouaud O, Barberger-
Gateau P, Ancelin ML. The neuro-protective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007 69:536-545.
53. Chen J-F, Sonsalla P, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV,
de Mendonça A. Adenosine A2A Receptors and Brain Injury: Broad Spectrum of Neuroprotection, Multi-Faced Actions and “Fine Tuning” Modulation. Progr Neurobiol 2007 83:310-331.
54. Ribeiro F, Guerreiro M, de Mendonça A. Cognitive deficits in mild cognitive impairment.
55. de Mendonça A. Editorial. J Nutr Health Aging 2008 12:50S. 56. Mendes T, Ginó S, Ribeiro F, Guerreiro M, de Sousa G, Ritchie K, de Mendonça A.
Memory complaints in healthy young and elderly adults: reliability of memory reporting Aging Ment Health 2008 12:177-182.
57. Silva D, Santana I, Simões do Couto F, Maroco J, Guerreiro M, de Mendonça A.
Cognitive deficits in middle-aged and older adults with bipolar disorder and cognitive complaints: Comparison with mild cognitive impairment. Int J Geriatr Psychiatry 2009 24:614-631.
58. Ginó S, Mendes T, Maroco J, Ribeiro F, Schmand BA, de Mendonça A, Guerreiro M,
Memory complaints are frequent but qualitatively different in young and old healthy people. Gerontology 2010 56:272-277.
59. Nunes T, Fragata I, Ribeiro F, Palma T, Maroco J, Cannas J, Secca M, Menezes C, Carmo
I, Cunha G, Castelo Branco M, Guerreiro M, de Mendonça A. The outcome of elderly patients with cognitive complaints but normal neuropsychological tests. J Alzheimers Dis 2010 19:137-145.
60. Pedrosa H, de Sá A, Guerreiro M, Maroco J, Simões MR, Galasko D, de Mendonça A.
Functional Evaluation distinguishes MCI patients from healthy elderly people - the ADCS/MCI/ADL scale. J Nutr Health Aging 2010 14:703-709.
61. de Mendonça A, Cunha RA. Editorial – Therapeutic opportunities for caffeine in
Alzheimer’s disease and other neurodegenerative disorders. J Alzheim Dis 20 (suppl 1): S1-S2, S249-S252.
62. Ana Rita Costenla AR, Cunha RA, de Mendonça A. Caffeine, adenosine receptors and
synaptic plasticity. J Alzheim Dis 2010 20 (suppl 1): S25-S34.
63. de Carvalho M, Marcelino E, de Mendonça A. Electrophysiological Studies in Healthy
Subjects Involving Caffeine. J Alzheim Dis 2010 20 (suppl 1): S63-S69.
64. Santos C, Lunet N, Azevedo A, de Mendonça A, Ritchie K, Barros H. Caffeine intake is
associated with a lower risk of cognitive decline: a cohort study from Portugal. J Alzheim Dis 2010 20 (suppl 1): S175-S185.
65. Nielsen TR, Vogel A, Riepe MW, de Mendonça A, Rodriguez G, Nobili F, Gade A,
Waldemar G. Assessment of dementia in ethnic minority patients in Europe – A European Alzheimer’s Disease Consortium survey. Int Psychogeriatr 2010 Jul 6:1-10 [Epub ahead of print).
66. Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The Use of
Neuropsychological Tests across Europe: The Need for a Consensus in the Use of Assessment Tools for Dementia. Eur J Neurol 2010 Jun 27 [Epub ahead of print].
67. Melo G, Maroco J, de Mendonça A. Influence of personality on caregiver’s burden,
depression and distress related to the BPSD. Int J Geriatr Psychiatry (in press).
Other recent international publications
1. de Mendonça A, Perry G. Obituary – Edgar da Cruz e Silva 1958-2010. J Alzheim DisRecent publications in national journals
1. Almeida MR, Guerreiro M, de Mendonça A. Familial frontotemporal dementia associated
with MAPT mutation: the first portuguese case. Sinapse 2006 6(1):75-78.
2. de Mendonça A. Editorial. Sinapse 2006 6(2):2-3. 3. de Mendonça A. Grupo de Estudos de Envelhecimento Cerebral e Demências – breve
nota histórica Sinapse 2006 6(2):49-50.
4. de Mendonça A. Abordagens terapêuticas no Defeito Cognitivo Ligeiro. Mundo Médico
5. de Mendonça A. Alzheimer – quando a memória nos atraiçoa. Saúde em Revista -Anuário
6. Marcelino E., de Mendonça A. The scientific production in the field of Alzheimer’s
disease in Portugal. Sinapse 2008 8 (1) 27-30.
7. de Mendonça A, Santana I, Valverde A. Doença de Alzheimer – Investigação Científica.
8. de Mendonça A. Grupo de Demências – Consórcio Europeu sobre Doença de Alzheimer.
9. de Mendonça A. Em Memória. Sinapse 2009 9(1) 43. 10. de Mendonça A. Não aprendas depressa. Sinapse 2009 9(2) 64. 11. de Mendonça A. O Grupo de Estudos de Envelhecimento Cerebral e Demências. Página
do Grupo de Estudos de Envelhecimento Cerebral e Demências, http://www.geecd.org/.
12. de Mendonça A, Santana I. Notícia. Página do Grupo de Estudos de Envelhecimento
Cerebral e Demências, http://www.geecd.org/.
13. de Mendonça A. Os efeitos benéficos do café. Café e Saúde, 2009. 14. Silva D, de Mendonça A, Guerreiro M. The Clock-Drawing Test – historical notes
followed by a few examples. Sinapse 2009 9(2) 52-57.
15. de Mendonça A. A doença de Alzheimer, hoje. Rev Port Clin Geral 2010 26 34-36. 16. de Mendonça A. Cafeína Para a Memória. Notícias Magazine, Diário de Notícias e Jornal
17. de Mendonça A. O Tratamento do Futuro. Dossier Saúde - Dia Mundial da Doença de
Alzheimer. Diário de Notícias e Jornal de Notícias, 21th September 2010.
1. de Mendonça A, Simões do Couto F. Terapêutica farmacológica da demência, in A
Doença de Alzheimer e Outras Demências, de Mendonça A e Castro Caldas A (eds). Lidel, Lisboa, 2005, pp. 111-120.
2. de Mendonça A. Um século de doença de Alzheimer, in Annualia. Editorial Verbo,
3. Ribeiro F, Guerreiro M, de Mendonça A. Defeito cognitivo ligeiro, in Psicogeriatria,
Firmino H, Cortez Pinto L, Leuschner A, Barreto J (eds.). Editora Psiquiatria Clínica, 2006, pp 315-331.
4. de Mendonça A, Garcia C: Demência, in Neurologia – Princípios, Diagnóstico e
Tratamento. Ferro JM, Pimentel JG (eds.). Lidel, 2006, pp 185-199.
5. Simões do Couto F, de Mendonça A. Aging and cognitive decline: neuroprotective
strategies, in Interaction Between Neurons and Glia in Aging and Disease. Malva J, Rego AC, Cunha RA, Oliveira CR (eds). Springer, 2007.
6. de Mendonça A, Melo G. A Tragédia de Esquecer: Doença de Alzheimer, in Toda a
Memória. Sousa M (ed.). Esfera do Caos, 2007.
7. Simões do Couto, Verdelho A, de Mendonça. Demência. In Manual de Terapêutica
Médica. Ponce P (coord). Lidel (in press).
8. Mendonça A, Guerreiro M (coordinators). Escalas e Testes na Demência. Grupo de
Estudos de Envelhecimento Cerebral e Demência, 2nd ed., 2008.
9. de Mendonça A. Envelhecimento e Dependência – O Caso das Doenças
Neurodegenerativas, in O Tempo da Vida. Principia, Lisboa, 2009.
1. de Mendonça A. Diagnóstico Temprano de la Enfermedad de Alzheimer. II Jornadas
Ibericas sobre Alzheimer, Madrid, April 2008.
2. de Mendonça A. Envelhecimento e Dependência – O Caso das Doenças
Neurodegenerativas. Forum Gulbenkian de Saúde 2008/2009, Lisbon, June 2008.
3. de Mendonça A. Neuroprotecção e Cafeína. Congresso de Neurologia, Porto, November
4. de Mendonça A. Demências Rapidamente Progressivas, Forum Futuro, Lisbon, April
5. de Mendonça A. Café e Demência. Forum SPESM 2009, Lisbon, June 2009.
6. de Mendonça A. Uso do Placebo, I Jornadas CEIC, Lisbon, January 2010. 7. de Mendonça A. Afinal Sempre É Doença de Alzheimer. Meeting of Hospital de Santa
8. de Mendonça A. Defeito Cognitivo no Idoso, Colóquio O Mundo do Idoso e O Idoso no
Mundo, Hospital de Santa Maria, March 2010.
9. de Mendonça A. Um Princípio de Alzheimer. Ciência 2010, Lisbon, July 2010. 10. de Mendonça A. Clinical Trials in Alzheimer’s Disease. Workshop Harvard Medical
School – Portugal, Molecular Mechanisms in Neurodegeneration: From Molecules to Cures, Sesimbra, July 2010.
11. de Mendonça A. Methodological Limitations and Type of Questions that Can Be
Addressed in Human Studies. Workshop on Coffee and Cognition in the Elderly, Paris, September 2010.
12. de Mendonça A. Clinical Aspects of Protein Misfolding and Aggregation. Short Course,
Sociedade Portuguesa de Biofísica, Santarém, October 2010.
13. de Mendonça A. Studies on Coffee /Caffeine in Alzheimer’s Disease and Other
Neurodegenerative disorders. 23th International Conference in Coffee Science, Bali, October 2010.
Cláudia Almeida. beta-amyloid-dependent neuronal dysfunction and effect on the endocytic pathway. 2007.Joana Coelho. Presynaptic mechanisms in the hypoxia-induced suppression of synaptic transmission in the rat hippocampus. 2010.
Tiago Mendes. Memory and metamemory: from the young to the aged. 2003.Bruno Silva. Absence of effect of ATP analogues on homosynaptic long-term depression in the CA1 region of rat hippocampal slices. 2004.Vânia Teixeira. Caffeine and synaptic plasticity: transcranial magnetic stimulation and neuropsychological evaluation. 2005.Dina Silva. Cognitive deficits in middle-aged and older patients with bipolar disorders: comparison with mild cognitive impairment subjects. 2008.Helena Pedrosa. Avaliação funcional em doentes com defeito cognitivo ligeiro. 2008.Erica Marcelino. Excitatory and inhibitory effects of caffeine in the neocortex – a transcranial magnetic stimulation study. 2010.
- 1 - ====================================================== F.I.D.A.L. F.P.C.M. XXXIX° T R O F E O A T Z W A N G E R Bronzolo/Aldino - Branzoll/Aldein 09.05.2010 ====================================================== Platz |St.Nr|Name |Verein |Kat|Jahr|Pkt.|Zeit |Abstand ---------|-----|--------------------------|---------------------|---|----|----|-----------|------------ 1. 2 Wyatt Jonathan
[ JAMA India (2001): (4), 8, 119-121] Antispasmodics – A New Perspective Kala Suhas Kulkarni, Medical Advisor, R&D Center, The Himalaya Drug Company, Makali, Bangalore, India. ABSTRACT Looking into the older perspectives and limitations of conventional anti-cholinergic, anti- spasmodics, there are needs to develop newer and safer anti-spasmodics for the management of